Pay a different price for the same cancer drug depending on the indication
One immunotherapy may add years of life in one cancer and weeks in another, yet costs the same. Prices should track the benefit in each use.
Multi-indication oncology drugs are priced at a single level, so payers either overpay for low-value indications or refuse them entirely. Indication-based pricing has been implemented through Italy's AIFA web-based registries and, in effect, through confidential indication-level rebates in some markets; the barrier elsewhere is that claims do not reliably record the indication. The proposal is mandatory indication coding at dispensing (linking the diagnosis code and line of therapy to the drug claim) and indication-level net prices set from value frameworks such as ESMO-MCBS or ICER thresholds.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.
Pages like this
not linked directly; found by shared links- IdeaAutomatic price cuts when a cancer drug's approved indications and volumes expand
Shares Prices and value, Pembrolizumab.
- IdeaCap public prices for new cancer drugs to tiers of the ESMO and ASCO value scales
Shares European Society for Medical Oncology (ESMO), Prices and value.
- IdeaSubscription pricing for checkpoint inhibitors: fixed national fee, unlimited use
Shares Prices and value, Pembrolizumab.
- IdeaRestore weight-based dosing and vial sharing for immunotherapy in the label
Shares Prices and value, Pembrolizumab.
- IdeaPublicly funded trials of lower and less frequent doses of expensive cancer drugs
Shares Prices and value, Pembrolizumab.
- IdeaPooled procurement and voluntary licensing for essential cancer medicines in low-income countries
Shares Prices and value, Pembrolizumab.
- IdeaAn advance market commitment for PD-1 biosimilars for lower-income countries
Shares Prices and value, Pembrolizumab.
- IdeaApprove cancer biosimilars on analytics and pharmacokinetics, no efficacy trials
Shares Prices and value, Pembrolizumab.